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About 13 beta-globin mutations encompass 70 - 90% of mutation spectrum in Iran. These mutations are 
called common beta-globin mutations. The rest are rare or unknown mutations. The objective of this 
study was to identify and describe rare or unknown beta-globin mutations in Qazvin province. EDTA-
containing venous blood samples were collected from 100 patients with transfusion-dependent beta-
thalassemia from the department of pediatrics of Qods hospital of Qazvin. Screening for causal 
mutations was carried out on DNA isolated from WBCs of the patients by using Amplification 
Refractory System (ARMS) technique. 14.1% of alleles which were not discovered by ARMS, were 
uncovered by direct sequencing that include 9 different rare mutations. Thirty-seven combinations of 
alleles (genotypes) were recognized in all affected patients. The frequency of mutations of nt-30, IVS I-6, 
Cd5, IVS II-745, 5´ UTR, Cd15, Cd39, IVS I-130, Cd24, Cd74/75, HbS and Hb Monroe were about 1% or 
less. We have revealed and described the existence of 9 rare mutations from Qazvin, two of which 
(Cd74/75 and Hb Monroe) are the first reported in Iran. 
 





Beta thalassemia is considered as the most common 
autosomal single-gene disorder world wide. it can be 
found in more than 60 countries with a carrier (hete-
rozygote) population of up to 150 - 200 million people or 
4.5% of the world population and at least 300000 lethally 
affected homozygotes are born annually (Kawthalklar, 
2006 ; Old et al., 1990).  
Iran, with more than 18000 affected individuals, repre-
sents one of the areas in the world with an unusually high 
prevalence of beta thalassemia. Provinces around the 
Persian Gulf and the Caspian Sea with a gene frequency 
of more than 10% constitute the thalassemia major zones 
in Iran (Najmabadi et al., 2003; Derakhshandeh et al., 
2007).  
The disease results from one or more of about 200 
different mutations in the beta globin gene (HBB). So 
there are numerous gene mutations responsible for beta 
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least 43 different mutations. Each province of Iran has its 
own characteristic spectrum of mutations, with a handful 
of frequent mutations and several rare ones. Searching 
for and identifying rare or new mutations is a constant 
priority in population screening, genetic counseling and 
prenatal diagnosis (PND) of thalassemia. About 13 beta-
globin mutations encompass 70 - 90% of mutation spec-
trum in Iran. These mutations are called common beta-
globin mutations (Roudkanar et al., 2003). The rest are 
rare or unknown mutations. In our past study we descry-
bed the spectrum of thalassemia mutations in Qazvin 
province (Sarookhani et al., 2009). The objective of 
current study is the analysis of rare or unexpected beta-
globin mutations in Qazvin. 
 
 
MATERIALS AND METHODS  
 
In an analytical-descriptive study venous blood samples (always 
prior to transfusion) were collected in EDTA-containing tubes from 
100 patients (9 related families and 91 unrelated) with transfusion-
dependent beta thalassemia major from the Department of 
Pediatrics of Qods Hospital of Qazvin.  
The age, sex, duration and start of transfusion and consanguinity 
(familial marriage)  between  parents  were  recorded  by  reviewing  




Table 1. Oligonucleotide primers used for mutation detection by direct sequencing. 
 
5´-TTGAGGATTCGGTCACGGTCTTCT -3´ Sequencing primer Sense 
5´-TTTTCCCTTACACCCTCCAGTCAC -3´ Sequencing primer Anti sense 
5´- CTTAGGCTGCTGGTGGTCTACC- 3´  Sequencing primer F 




Table 2. Degree of incidence of various mutations in beta thalassemia major 
patients of Qazvin province.  
 
incidence mutation No. and % of alleles Frequency (%) 
Ivs 2/1 57 (31.3%) 
Ivs 1/110 35 (19.2%) 
 
HIGH 
Fsc 8/9 16 (8.8%) 
59.3% 
Codon 30 9 (4.95%) 
Codon 44 11 (6.05%) 
Ivs 1/5 10 (5.5%) 





 Ivs 1/1 8 (4.4%) 
25.85% 
nt -30 4 (2.2%) 
Ivs 1/6 3 (1.65%) 
Codon 5 3 (1.65%) 
Ivs 2/745 2 (1.1%) 
5 UTR 2 (1.1%) 
Codon 15 2 (1.1%) 
Codon 39 2 (1.1%) 
















Codon 24 1 (0.55%) 












their files after obtaining their (or parents) permission.  
DNA extraction from samples and Amplification Refractory Sys-
tem (ARMS) technique for screening of common thalassemia muta-
tions were performed as described before (Sarookhani et al., 2009; 
Najmabadi et al., 2001). 
A total of 13 samples, which remained negative for common or 
prevalent mutations, were subjected to DNA sequencing of the 
beta-globin gene. To identify the rare beta thalassemia alleles of 
the study, two region of beta globin of the samples were amplified 
by two sets of primers (sense, anti sense, F primer and R primer) 
(Table 1) designed for initial site, exon I, intron I as well as exon II 
and intron II of the gene (Mirasena et al., 2007). These primers 
were synthesized in ATG Copenhagen, Denmark. The resulting 
segments (850 and 500 bp) and nucleotides respectively, contain 
most of the known mutant sites specific for the Mediterranean 
population.  
Following amplification, the PCR products were purified, using an 
ABI purification kit. The purified samples were sequenced using the 
dideoxy termination procedure of Sanger (Sanger, 1997) by an 
automated sequencer analyzer (ABI-3730XL Capillary, Applied 
Biosystem, USA) as per the manufacture's instructions. Compa-
risons of sequencing results with normal beta-globin gene sequen-





The various mutations in unrelated transfusion dependent 
beta thalassemias (91 patients) of Qazvin province 
according their degree of incidences are given in Table 2.  
Based on these results, the frequency of different kinds 
of low frequent and rare mutations was 14.85%. Muta-
tions of nt-30, IVS I-6, Cd5, IVS II-745, 5 UTR, Cd15, 
Cd39, IVS I-130, Cd24, Cd74/75 HbS and Hb Monroe 
were observed rarely (about 1% or less) in this region. 
One patient (2 alleles) remained unknown. Most of these 
rare mutations (alleles) in patients, were co-inherited (in 
combination) with frequent mutations (combined hete-





Table 3. Genotype frequencies of thalassemia major 
population (all relatives and non-relatives) of Qazvin province. 
 
No. Genotype Frequency (%) 
1 Ivs 2/1, Ivs 2/1 18 
2 Ivs 1/110, Ivs 1/110 10 
3 Fsc 8/9, Fsc 8/9 5 
4 Codon 44, Codon 44 1 
5 Ivs 2/1 , Ivs 1/110 13 
6 Codon 30 , Ivs 2/1 6 
7 Ivs 1/1 , Ivs 1/110 4 
8 Ivs 1/5 , Ivs 2/1 4 
9 Codon 44 , Ivs 2/1 4 
10 Ivs 2/1 , Codon 5 1 
11 Codon 44 , Codon 30 1 
12 Codon 5 , Codon 44 1 
13 Ivs 1/110 , Codon 44 1 
14 vs 1/5 , Codon 44 2 
15 Ivs 2/745 , Ivs 2/1 1 
16 Ivs 1/1 , Ivs 2/1 1 
17 Codon 44 , Ivs 2/745 1 
18 Ivs 1/6 , Ivs 1/5 1 
19 Fsc 8/9 , Ivs 2/1 1 
20 Codon 30, Codon 30 1 
21 Fsc 8/9 , 5 UTR 1 
22 Fsc 36/37, Fsc 36/37 5 
23 Fsc 8/9 , Codon30 1 
24 Ivs 1/1, Ivs 1/1 1 
25 Ivs 1/1 , Ivs 1/130 1 
26 Codon 24 , Codon 30 2 
27 Fsc 8/9 , Hbs 1 
28 Codon 39, Codon 39 1 
29 Codon 15 , Codon 15 1 
30 Ivs 1/5 , Ivs 1/5 1 
31 5 UTR , Ivs1/5 1 
32 Ivs 1/6 , Ivs 1/6 1 
33 Codon 5,Codon 74/75 1 
34 Fsc 8/9 , Ivs 1/130 1 
35 Fsc 8/9 , Fsc 36/37 1 
36 nt -30 , nt -30 2 
37 No mutation 1 




of alleles (genotypes) were recognized (Table 3). Se-
quencing chromatograms of some rare mutations are 





Qazvin is a small province with population of about 1.2 
million, suited in the north of Iran between Tehran, Gilan, 
Mazandaran, Zanjan and Hamedan provinces. It is  worth  




mentioning that due to bulky ethnic (genetic) admixture 
and relatively rich genetic pool in such small province like 
Qazvin, the distribution of low frequent or rare mutations 
are high. Two of these mutations were unique to Qazvin 
province and have not been discovered in any other 
provinces of Iran. Several interesting descriptions come 
from the analysis of different kinds of rare mutations of 
our results, discussed below. 
Nucleotide -30(nt -30) (T to A)) was reported in Iran as 
a rare transcriptional mutation with a frequency of 0.15% 
(Yavarian, 2005). This mutation has Turkish-Iranian origin 
(Najmabadi et al., 2002) with + phenotype and thalas-
semia intermedia or even without presentations (Çidem, 
2002; Oner et al., 2001). Both index cases in homo-
zygous form of our study (Figure 1A) have Turkish origin 
and thalassemia intermedia phenotypes. 
5 ´UTR (+22) (G to A) cap site mutation has been re-
ported very rarely (0.04%) in Iran (Yavarian, 2005; 
Najmabadi et al., 2002) in Turkish ethnic groups. Its pre-
sentations is + thalassemia intermedia in homozygous 
form (Çidem, 2002). In our study both alleles of this 
mutation have been inherited as compound heterozygote 
(5´ UTR / IVS I-5 and 5´ UTR / FSC 8 - 9 genotypes). 
Codon 15 (TGG to TGA or stop codon) as a rare non-
sense mutation has been reported in Iran by Najmabadi 
et al. (3 alleles of Portuguese and 1 allele of Asian-Indian 
(TGG to TAG) types) (Najmabadi et al., 2002). It has 
0.11% overall frequency in Iran (Yavarian, 2005). In pre-
sent study this mutation was detected in homozygous 
form (Figure 1B) of Portuguese type in a Turkish patient. 
IVS I-130 mutation ( G to C) with a Turkish-Iranian 
origin was reported as a most common of rare mutations 
in Iran by Najmabadi et al. (11 allele), Rahim et al. (1 
allele ) and Roudkanar et al. (4 allele) (Najmabadi et al., 
2002; Rahim et al., 2007; Roudkanar et al., 2003). In pre-
sent study this mutation was observed in 2 cases with 
Turkish origin in compound heterozygote forms (IVS I-1 / 
IVS I-130 and FSC 8 - 9 / IVS I-130 genotypes). Yavarian 
has reported a frequency of 0.41% for this mutation in 
Iran (Yavarian, 2005). 
Codon24 (GGT to -GT) mutation was reported very 
rarely (0.04%) in Iran (Yavarian, 2005, Najmabadi et al., 
2002). In present study only one allele of this mutation in 
combination with Codon30 mutation (Codon 24/ Codon 
30 genotype) was detected. 
HbS (GAG to GTG; Glu to Val) is a common hemo-
globinopathy in south of Iran (Rahimi et al., 2006). It can 
be co-inherited with different kinds of thalassemia muta-
tions (sickle-thalassemia or double heterozygote condi-
tions). To the best of our knowledge it has not been 
reported in north of Iran in literature reviews. In present 
study it was detected in the form of FSC 8 - 9/ HbS geno-
type producing severe phenotype of beta thalassemia 
major. Rahimi et al. was reported such genotype in south 
of Iran (Rahimi et al., 2006). 
Hb Monroe (beta 30, G to C or IVS I(-1) ) results from a 
splice site point mutation in the last nucleotide of beta-globin  






Figure 1A. Sequence obtained from automated DNA sequencing of some uncharacterized (by ARMS technique) 
thalasemia major samples in Qazvin province. nt-30 mutation: There is a transition of T to A in promoter region 






Figure 1B. Sequence obtained from automated DNA sequencing of some uncharacterized (by ARMS technique) 
thalasemia major samples in Qazvin province. Codon 15 mutation: There is a substitution of G to A in codon 15, 
changing Trp codon (TGG) to stop codon (TGA), homozygote case. 






Figure 1C. Sequence obtained from automated DNA sequencing of some uncharacterized (by ARMS technique) thalasemia major 
samples in Qazvin province. Codon 74/75mutation: There is a deletion of C at last nucleotide of codon 74 (GGC CTG to GG- 




exon1 which is also the penultimate nucleotide of codon 
30 of the beta-globin peptide (AGG to ACG ; Arg to Thr). 
After the original reports in 1989, Hb Monroe has been 
reported in low frequency, mostly in compound hetero-
zygosity with other beta globin mutations (Agarwal et al., 
2007). We have already reported this mutation in Iran 
(Sarookhani et al., 2009) which co-inherited with IVS II-1 
(Figure 1D). Before this, there is no report of such 
mutation and genotype in Iran (Roudkanar et al., 2003; 
Yavarian, 2005; Najmabadi et al., 2002; Najmabadi et al., 
2001).  
Codon74/75 (GGC CTG to GG- CTA) is a rare frame 
shift mutation in the world with º phenotype in Turkish 
ethnic groups (Çidem, 2002). It was detected in com-
pound heterozygote form (Codon 5/ Codon 74/75) in one 
allele of the present study (Figure 1C). A literature search 
has shown that this is the first report of this mutation from 
Iran and has not been reported by any author in their 
reviews on thalassemia mutation in Iran.  
In spite of having thalassemia major phenotype, one 
patient (2 alleles) detected as "no mutation". This case 
need to be subjected to further detailed investigations 
which include analysis of the beta-globin gene that could 






Heterogeneity of beta-thalassemia mutations in a quite 
small area may be regarded as footprints of many popu-
lation movements. The present study indicates that the 
frequency of mutations at Qazvin province is different 
than the mutation frequency profile given for Iran. Several 
combinations of alleles detected here may be considered 
important in terms of understanding of molecular defects 
causing beta-thalassemia. We also identified different 
kinds of rare and new mutations in the population of the 
Qazvin province, two of which (Cd74/75 and Hb Monroe) 
as reported previously (Sarookhani et al., 2009) are the 
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Figure 1D. Sequence obtained from automated DNA sequencing of some uncharacterized (by ARMS technique) thalasemia 
major samples in Qazvin province. Hb Monroe mutation: There is a substitution of G to C in the last nucleotide of beta-globin 
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